Arbutus Biopharma Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arbutus Biopharma Corporation
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.
Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.
Medilink’s ADC platform, which addresses the antibody endocytosis process, has received its first endorsement from a major international partner in the form of BioNTech.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Genevant Sciences
- Inex Pharmaceuticals Corporation
- OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
- Tekmira Pharmaceuticals Corporation (TKMR)
- Protiva Biotherapeutics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.